| NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES OF CONTINUING OPERATIONS | -9.07M |
| NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES OF DISCONTINUED OPERATIONS | |
| Purchases of property, plant and equipment | -6.4M |
| Proceeds from the sale of intangible assets | 74K |
| Purchase of intangible assets | -2.48M |
| Purchase of ECR Pharmaceuticals assets | |
| NET CASH (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS | -10.72M |
| Issuance of common stock and exercise of options | 5.49M |
| Tax benefits of stock incentives | 1.39M |
| Borrowings from long-term debt | |
| Payment of capital lease obligation | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS | 5.63M |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | -14.16M |
| Cash and cash equivalents at beginning of the period | 100.61M |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 86.45M |
| Interest paid | 245K |
| Income taxes paid | 11.23M |
| Obligation related to purchase of intangible assets included in accrued expenses | |